ArticleDrug safety2022
Black Swan Events and Intelligent Automation for Routine Safety Surveillance.
Article in Drug safety, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Biomedical Large Language Models and Prompt Engineering for Causality Assessment of Individual Case Safety Reports in Pharmacovigilance.Pharmaceutical research · 2026Article
- Augmenting Medical Judgment in Signal Confirmation: Design Considerations for an AI-Enabled Causality Assessment Framework.Drug safety · 2026Review
- Critical Appraisal of Artificial Intelligence for Rare-Event Recognition: Principles and Pharmacovigilance Case Studies.Drug safety · 2026Article
- Actual Challenges and Future Horizons of Cultural Psychology.Integrative psychological & behavioral science · 2026Article
- Occurrence of antibacterials, antivirals, and anti-inflammatory pharmaceuticals for COVID-19 treatment as emerging contaminants in the Chinese freshwater environment before, during and after the pandemic: the need for dynamic eco-pharmacovigilance.Environmental health and preventive medicine · 2026Review
- How is AI developing in pharmacovigilance?Therapeutic advances in drug safety · 2026Article
- Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?Drug safety · 2025Article
- Artificial Intelligence: Applications in Pharmacovigilance Signal Management.Pharmaceutical medicine · 2025Review
- Orchestrating generative AI in pharmacovigilance: predicting and preempting the unpredictable.Therapeutic advances in drug safety · 2025Review
- Pharmacovigilance in the Age of Legalized Cannabis: Using Social Media to Monitor Drug-Drug Interactions Between Immunosuppressants and Cannabis-Derived Products.Drug safety · 2025Article
- Digital Transformation of Public Health for Noncommunicable Diseases: Narrative Viewpoint of Challenges and Opportunities.JMIR public health and surveillance · 2024Article
- Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed?Therapeutic advances in drug safety · 2024Article
- An industry perspective on the use of machine learning in drug and vaccine safety.Frontiers in drug safety and regulation · 2023Article
- Twenty-First Century Global ADR Management: A Need for Clarification, Redesign, and Coordinated Action.Therapeutic innovation & regulatory science · 2023Article
- Artificial Intelligence and Machine Learning for Safe Medicines.Drug safety · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Effective identification of previously implausible safety signals is a core component of successful pharmacovigilance. Timely, reliable, and efficient data ingestion and related processing are critical to this. The term 'black swan events' was coined by Taleb to describe events with three attributes: unpredictability, severe and widespread consequences, and retrospective bias. These rare events are not well understood at their emergence but are often rationalized in retrospect as predictable. Pharmacovigilance strives to rapidly respond to potential black swan events associated with medicine or vaccine use. Machine learning (ML) is increasingly being explored in data ingestion tasks. In contrast to rule-based automation approaches, ML can use historical data (i.e., 'training data') to effectively predict emerging data patterns and support effective data intake, processing, and organisation. At first sight, this reliance on previous data might be considered a limitation when building ML models for effective data ingestion in systems that look to focus on the identification of potential black swan events. We argue that, first, some apparent black swan events-although unexpected medically-will exhibit data attributes similar to those of other safety data and not prove algorithmically unpredictable, and, second, standard and emerging ML approaches can still be robust to such data outliers with proper awareness and consideration in ML system design and with the incorporation of specific mitigatory and support strategies. We argue that effective approaches to managing data on potential black swan events are essential for trust and outline several strategies to address data on potential black swan events during data ingestion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.